The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10447 malaria professionals are enjoying the free benefits of MalariaWorld today

Artemisinin

Open Access | Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription

August 3, 2011 - 12:10 -- Patrick Sampao
Author(s): 
Sachel Mok, Mallika Imwong, Zbynek Bozdech, et al.
Reference: 
BMC Genomics 2011, 12:391

This study reports the first global transcriptional survey of artemisinin resistant parasites and provides insight to the complexities of the molecular basis of pathogens with drug resistance phenotypes in vivo.

Medical Treatment: 

Open Access | Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion

July 13, 2011 - 07:02 -- Kabogo Ndegwa
Author(s): 
Nectarios Klonis, Maria P. Crespo-Ortiz, Iveta Bottova, Nurhidanatasha Abu-Bakar, Shannon Kenny, Philip J. Rosenthal, and Leann Tilley
Reference: 
PNAS July 12, 2011 vol. 108 no. 28 11405-11410

Combination regimens that include artemisinin derivatives are recommended as first line antimalarials in most countries where malaria is endemic

Medical Condition: 
Medical Treatment: 

Pharmaceutical Nanotechnology: Absorption of the novel artemisinin derivatives artemisone and artemiside: Potential application of Pheroid™ technology

June 28, 2011 - 12:41 -- Patrick Sampao
Author(s): 
J. Dewald Steyn, Lubbe Wiesner, Lissinda H. du Plessis, Anne F. Grobler, Peter J. Smith, Wing-Chi Chan, Richard K. Haynes, Awie F. Kotzé
Reference: 
International Journal of Pharmaceutics, Volume 414, Issues 1-2, 29 July 2011, Pages 260-266

Pharmacokinetic models were constructed for artemisone and artemiside in Pheroid™ vesicle formulations. The compounds were administered at a dose of 50.0 mg/kg bodyweight to C57 BL/6 mice via an oral gavage tube and blood samples were collected by means of tail-bleeding.

Technology: 

Effects of highly active novel artemisinin–chloroquinoline hybrid compounds on β-hematin formation, parasite morphology and endocytosis in Plasmodium falciparum

June 28, 2011 - 06:57 -- Kabogo Ndegwa
Author(s): 
Tzu-Shean Feng, Eric M. Guantai, Margo Nell, Constance E.J. van Rensburg, Kanyile Ncokazi, Timothy J. Egan, Heinrich C. Hoppe, Kelly Chibale
Reference: 
Biochemical Pharmacology, Volume 82, Issue 3, 1 August 2011, Pages 236-247

4-Aminoquinolines were hybridized with artemisinin and 1,4-naphthoquinone derivatives via the Ugi-four-component condensation reaction, and their biological activities investigated.

Medical Condition: 
Medical Treatment: 

Open Access | Safety, pharmacokinetics and efficacy of artemisinins in pregnancy

June 15, 2011 - 14:42 -- Kabogo Ndegwa
Author(s): 
Veronica Ades
Reference: 
Infectious Disease Reports, Vol 3, No 1 (2011)

Malaria in pregnancy can lead to serious maternal and fetal morbidity and mortality. Access to the most effective antimalarials in pregnancy is essential.

Medical Condition: 
Medical Treatment: 

Open Access | Increasing Access to Subsidized Artemisinin-based Combination Therapy through Accredited Drug Dispensing Outlets in Tanzania

June 13, 2011 - 13:03 -- Patrick Sampao
Author(s): 
Edmund Rutta, Bryceson Kibassa, Hiiti Sillo, et al.
Reference: 
Health Research Policy and Systems 2011, 9:22, 9 June 2011

This paper presents a description of the pilot program implementation, results of the program evaluation, and a discussion of the challenges and recommendations that will be used to guide rollout of subsidized ACT in ADDOs in the rest of Tanzania and probably in other countries.

Country: 
Medical Treatment: 

Therapeutic Efficacies of Artemisinin-Based Combination Therapies in Nigerian Children with Uncomplicated Falciparum Malaria during Five Years of Adoption as First-Line Treatments

June 3, 2011 - 09:30 -- Patrick Sampao
Author(s): 
Grace O. Gbotosho, Akintunde Sowunmi, Christian T. Happi, and Titilope M. Okuboyejo
Reference: 
Am J Trop Med Hyg 2011 84:936-943

The therapeutic efficacies of 3-day regimens of artesunate-amodiaquine and artemether-lumefantrine during 5 years of adoption as first-line treatments were evaluated in 811 ≤ 12-year-old malarious children.

Person: 
Country: 
Medical Condition: 
Medical Treatment: 

Open Access | Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria

May 10, 2011 - 08:09 -- Kabogo Ndegwa
Author(s): 
Carrie A Morris, Marie A Onyamboko, Edmund Capparelli, Matthew A Koch, Joseph Atibu, Vicky Lokomba, Macaya Douoguih, Jennifer Hemingway-Foday, David Wesche, Robert W Ryder, Carl Bose, Linda Wright, Antoinette K Tshefu, Steven Meshnick, Lawrence Fleckenstein
Reference: 
Malaria Journal 2011, 10:114 (8 May 2011)

In this analysis, pharmacokinetic modelling suggests that pregnant women have accelerated DHA clearance compared to non-pregnant women receiving orally administered AS.

Person: 
Medical Condition: 
Medical Treatment: 

Open Access | New hope in the fight against malaria?

March 29, 2011 - 06:55 -- Kabogo Ndegwa
Author(s): 
Tiago Rodrigues, Rui Moreira and Francisca Lopes
Reference: 
Future Medicinal Chemistry, January 2011, Vol. 3, No. 1, Pages 1-3

Malaria is still one of the major vector-borne infectious diseases in the world.

Organization: 
Medical Condition: 
Medical Treatment: 

Open Access | Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria

March 17, 2011 - 08:13 -- Kabogo Ndegwa
Author(s): 
Susan A. Charman, Sarah Arbe-Barnes, Jonathan L. Vennerstrom, et al.
Reference: 
PNAS March 15, 2011 vol. 108 no. 11 4400-4405

Ozonide OZ439 is a synthetic peroxide antimalarial drug candidate designed to provide a single-dose oral cure in humans.

Medical Condition: 
Medical Treatment: 

Pages

Subscribe to RSS - Artemisinin